Precision BioSciences Inc (DTIL)

[NY1972]

No immunosuppressive regimen needed for in vivo edit

The company also announced the VX-880 Phase 1/2 study has been placed on clinical hold in the U.S. by the Food and Drug Administration (FDA) due to a determination that there is insufficient information to support dose escalation with the product.

https://www.businesswire.com/news/home/20220502005336/en/Vertex-Provides-Updates-on-Phase-12-Clinical-Trial-of-VX-880-for-the-Treatment-of-Type-1-Diabetes